Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.8905
+0.0317 (3.69%)
At close: May 12, 2025, 4:00 PM
0.8929
+0.0024 (0.27%)
After-hours: May 12, 2025, 6:55 PM EDT
Clearside Biomedical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Clearside Biomedical stock have an average target of 5.20, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 483.94% from the current stock price of 0.89.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 8, 2025.
Analyst Ratings
The average analyst rating for Clearside Biomedical stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +349.19% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +573.78% | Mar 31, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +461.48% | Mar 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +573.78% | Mar 28, 2025 |
| Needham | Needham | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +349.19% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
839.32K
from 1.66M
Decreased by -49.56%
Revenue Next Year
6.51M
from 839.32K
Increased by 675.15%
EPS This Year
-0.44
from -0.47
EPS Next Year
-0.66
from -0.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.7M | 21.3M | 49.7M | ||
| Avg | 839,317 | 6.5M | 20.6M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.0% | 2,438.4% | 663.9% | ||
| Avg | -49.6% | 675.2% | 216.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.25 | -0.26 | -0.29 | ||
| Avg | -0.44 | -0.66 | -0.47 | ||
| Low | -0.61 | -1.20 | -0.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.